This biotechnology company develops novel health treatments utilizing genetically engineered viruses. Their platform focuses on repurposing viruses, such as the Zika virus, into therapeutic agents. The company is advancing a pipeline of biotherapeutics based on this specialized viral vector technology.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Central nervous system (CNS) tumors, including those in adults and children, present significant treatment challenges due to their aggressive nature. Current treatment options often lack the specificity needed to target malignant cells effectively, leading to potential harm to healthy brain tissue. There is a need for more effective and targeted therapies for these tumors.
Solution
Vyro is developing genetically engineered oncolytic viruses based on the Zika virus to selectively target and destroy CNS tumors. The company's technology modifies the Zika virus to specifically attack malignant tumor cells while sparing healthy neurons and other cells in the CNS. This engineered virus exhibits oncolytic properties, meaning it can replicate within cancer cells, leading to their lysis and subsequent tumor regression. Preclinical research has demonstrated complete tumor remission in mice, suggesting a promising and safe alternative to traditional treatments. The platform aims to provide a safe and efficient therapeutic approach that can be scaled for pharmaceutical manufacturing.
Target Audience
The primary target audience includes healthcare professionals specializing in oncology and neuro-oncology, as well as adult and pediatric patients diagnosed with aggressive CNS tumors.
Features
- Genetically engineered Zika virus platform for targeted cancer therapy
- Oncolytic viruses designed to selectively target and destroy CNS tumor cells
- Engineered virus exhibits specificity for malignant cells, sparing healthy neurons
- Demonstrated complete tumor remission in mice during preclinical studies
- Scalable manufacturing process for pharmaceutical production